ClinicalTrials.gg
CompletedNCT04675151Updated Oct 30, 2026Results posted

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

A Phase 2 interventional study of Phentolamine Ophthalmic Solution 0.75% and Pilocarpine in Presbyopia, sponsored by Opus Genetics, Inc. Completed at 17 sites in United States. Open to participants aged 40 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment

Updated Oct 30, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
40 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing pilocarpine in Presbyopia — 2 open to participants now, 2 under way, 1 of them phase 3. Pilocarpine · Presbyopia.

Enrollment
6th of 10
150 · median 190
Started
2021
with 2 others
Phase 2
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
2 of 10
Opus Genetics, Inc

Among the 10 studies testing pilocarpine in Presbyopia, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is the only one in phase 2, and was the 4th registered.

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

Browse Presbyopia studies →

Open to participants now

2 of the 10 studies testing pilocarpine in Presbyopia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About pilocarpine

Pilocarpine: first FDA approval 1974 (OCUSERT PILO-20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Presbyopia studies recruiting now, 7 (39%) set no upper age limit and 9 (50%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 40 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pilocarpine in Presbyopia, or all of them as a file.
02

Study summary

The objectives of this study are:

To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia

03

Conditions studied

  • Presbyopia

Browse trials for

Keywords

  • Nyxol
  • Presbyopia
  • Pilocarpine
04

Who can participate

Ages eligible
40 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 40 and ≤ 64years of age.
  2. BCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic conditions.
  3. DCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse under photopic conditions in each eye and binocularly.
  4. Subjects who depend on reading glasses or bifocals in which their binocular best-corrected near VA is 0.1 LogMAR (20/25 Snellen equivalent) or better.

Exclusion criteria

Exclusion Criteria:

Ophthalmic (in either eye):

  1. Use of any topical prescription or OTC ophthalmic medications of any kind within 7 days of Screening until study completion.
  2. Use of any over-the-counter (OTC) artificial tears (preserved or unpreserved) at least once per day within 7 days of Screening until study completion.
  3. Current use of any topical ophthalmic therapy for dry eye.
  4. Tear break-up time of \< 5 seconds or corneal fluorescein staining.
  5. ocular disease that might interfere with the study as deemed by the Investigator.
  6. Recent or current evidence of ocular infection or inflammation in either eye.
  7. Any history of herpes simplex or herpes zoster keratitis.
  8. History of diabetic retinopathy or diabetic macular edema.
  9. Known allergy, , or to any component of the phentolamine, pilocarpine, or vehicle formulations.
  10. History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal.
  11. Ocular trauma, ocular surgery, ocular laser treatment within the 6 months prior to Screening. Any subject with multifocal intraocular lenses are excluded.
  12. History of any traumatic (surgical or nonsurgical) or non traumatic condition affecting the pupil or iris.
  13. Unwilling or unable to discontinue use of contact lenses.
  14. Conjunctival hyperemia ≥ grade 2 on the CCLRU 4-point scale.

    Systemic:

  15. Known hypersensitivity or contraindication to alpha- and/or beta adrenoceptor antagonists.
  16. Known hypersensitivity or contraindication to any systemic cholinergic parasympathomimetic agents.
  17. Clinically significant systemic disease that might interfere with the study as deemed by the Investigator.
  18. Participation in any study within 30 days prior to Screening.
  19. Females of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of .
  20. Resting HR outside the specified range of 50 to 110 beats per minute.
  21. Hypertension with resting diastolic BP > 105 mmHg or systolic BP > 160 mmHg.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Nyxol + Pilocarpine

    1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)

    Drug: Phentolamine Ophthalmic Solution 0.75% · Drug: Pilocarpine

  • Active comparator
    Nyxol

    1 drop of Nyxol (Treatment 1)

    Drug: Phentolamine Ophthalmic Solution 0.75%

  • Active comparator
    Pilocarpine

    1 drop of Pilocarpine (Treatment 2)

    Drug: Pilocarpine · Other: Placebo

  • Placebo comparator
    Placebo

    1 drop of Placebo (Treatment 1)

    Other: Placebo

Interventions

  • 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

    Also known as: Nyxol, Nyxol®

  • Pilocarpine ophthalmic solution

  • OtherPlacebo

    Topical sterile ophthalmic solution

    Also known as: Phentolamine Ophthalmic Solution Vehicle

06

What researchers measure

Primary outcomes

  1. Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA

    The primary efficacy endpoint was the percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA on Visit 2 at 1 hour with POS + LDP compared to placebo alone. The improvement in binocular DCNVA for each subject was relative to the subject's own baseline value (Visit 1).

    Time frame: Visit 2 at 1 hour

Secondary outcomes

  1. Percentage of Subjects With Improvement of ≥ 5, ≥ 10, and ≥ 15 Letters in DCNVA (Photopic) From Baseline

    The percentage of subjects with improvement of ≥ 5, ≥ 10, and ≥ 15 letters in DCNVA (photopic) from Baseline at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours

    Time frame: Visit 2 at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours

  2. Percentage of Subjects With Improvement of ≥ 15 Letters in DCNVA (Photopic) at 1 Hour and With < 5 Letters of Loss in Photopic Binocular BCDVA From Baseline

    The percentage of subjects with improvement of ≥ 15 letters in DCNVA (photopic) at 1 hour and with \< 5 letters of loss in photopic binocular BCDVA from Baseline

    Time frame: Visit 2 at 1 hour

  3. Percentage of Subjects With Improvement in DCIVA (Photopic) From Baseline

    The percentage of subjects with improvement in DCIVA (photopic) from Baseline of ≥ 5, ≥ 10, and ≥ 15 letters

    Time frame: Visit 2 at 1 hour, at 3 hours, and at 6 hours

07

Results

Posted Aug 2, 2023

Participant flow

Participant flow — Overall Study
MilestonePOS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP Vehicle
Started44303145
Completed43303144
Not completed1001
Withdrew: Protocol violation1001

Outcome measures

PrimaryPercent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA

The primary efficacy endpoint was the percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA on Visit 2 at 1 hour with POS + LDP compared to placebo alone. The improvement in binocular DCNVA for each subject was relative to the subject's own baseline value (Visit 1).

Time frame:
Visit 2 at 1 hour
Reported as:
Number · percentage of subjects with ≥ 15 letters
Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA
percentage of subjects with ≥ 15 lettersPOS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP Vehicle
Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA60.530.045.227.3
SecondaryPercentage of Subjects With Improvement of ≥ 5, ≥ 10, and ≥ 15 Letters in DCNVA (Photopic) From Baseline

The percentage of subjects with improvement of ≥ 5, ≥ 10, and ≥ 15 letters in DCNVA (photopic) from Baseline at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours

Time frame:
Visit 2 at 0.5 hours, at 2 hours, at 3 hours, at 4 hours, and at 6 hours
Reported as:
Number · percentage of subjects with improvement
Percentage of Subjects With Improvement of ≥ 5, ≥ 10, and ≥ 15 Letters in DCNVA (Photopic) From Baseline
percentage of subjects with improvementPOS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP Vehicle
% of subjects with improvement of ≥ 5 letters from baseline at 0.5 hours88.486.774.270.5
% of subjects with improvement of ≥ 10 letters from baseline at 0.5 hours76.750.054.852.3
% of subjects with improvement of ≥ 15 letters from baseline at 0.5 hours60.533.325.815.9
% of subjects with improvement of ≥ 5 letters from baseline at 2 hours88.493.383.970.5
% of subjects with improvement of ≥ 10 letters from baseline at 2 hours81.460.071.045.5
% of subjects with improvement of ≥ 15 letters from baseline at 2 hours62.826.741.918.2
% of subjects with improvement of ≥ 5 letters from baseline at 3 hours95.383.383.972.7
% of subjects with improvement of ≥ 10 letters from baseline at 3 hours67.460.064.543.2
% of subjects with improvement of ≥ 15 letters from baseline at 3 hours46.526.748.420.5
% of subjects with improvement of ≥ 5 letters from baseline at 4 hours95.383.383.975.0
% of subjects with improvement of ≥ 10 letters from baseline at 4 hours67.460.051.650.0
% of subjects with improvement of ≥ 15 letters from baseline at 4 hours46.530.032.320.5
% of subjects with improvement of ≥ 5 letters from baseline at 6 hours88.486.771.072.7
% of subjects with improvement of ≥ 10 letters from baseline at 6 hours67.460.054.850.0
% of subjects with improvement of ≥ 15 letters from baseline at 6 hours37.236.722.618.2
SecondaryPercentage of Subjects With Improvement of ≥ 15 Letters in DCNVA (Photopic) at 1 Hour and With < 5 Letters of Loss in Photopic Binocular BCDVA From Baseline

The percentage of subjects with improvement of ≥ 15 letters in DCNVA (photopic) at 1 hour and with \< 5 letters of loss in photopic binocular BCDVA from Baseline

Time frame:
Visit 2 at 1 hour
Reported as:
Number · % of subjects with improvement
Percentage of Subjects With Improvement of ≥ 15 Letters in DCNVA (Photopic) at 1 Hour and With < 5 Letters of Loss in Photopic Binocular BCDVA From Baseline
% of subjects with improvementPOS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP Vehicle
Percentage of Subjects With Improvement of ≥ 15 Letters in DCNVA (Photopic) at 1 Hour and With < 5 Letters of Loss in Photopic Binocular BCDVA From Baseline60.530.041.927.93
SecondaryPercentage of Subjects With Improvement in DCIVA (Photopic) From Baseline

The percentage of subjects with improvement in DCIVA (photopic) from Baseline of ≥ 5, ≥ 10, and ≥ 15 letters

Time frame:
Visit 2 at 1 hour, at 3 hours, and at 6 hours
Reported as:
Number · percentage with improvement
Percentage of Subjects With Improvement in DCIVA (Photopic) From Baseline
percentage with improvementPOS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP Vehicle
% of subjects with improvement of ≥ 5 letters from baseline at 1 hour86.046.771.056.8
% of subjects with improvement of ≥ 10 letters from baseline at 1 hour48.823.345.225.0
% of subjects with improvement of ≥ 15 letters from baseline at 1 hour14.010.022.64.5
% of subjects with improvement of ≥ 5 letters from baseline at 3 hours69.843.367.750.0
% of subjects with improvement of ≥ 10 letters from baseline at 3 hours41.930.041.925.0
% of subjects with improvement of ≥ 15 letters from baseline at 3 hours18.610.022.64.5
% of subjects with improvement of ≥ 5 letters from baseline at 6 hours72.156.738.747.7
% of subjects with improvement of ≥ 10 letters from baseline at 6 hours30.216.729.018.2
% of subjects with improvement of ≥ 15 letters from baseline at 6 hours14.010.012.94.5

Adverse events

Collected over 9 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
POS 0.75% First, Then LDP 0.4%0/44 (0%)0/44 (0%)15/44 (34.1%)
POS 0.75% First, Then LDP Vehicle0/30 (0%)0/30 (0%)6/30 (20%)
POS Vehicle First, Then LDP 0.4%0/31 (0%)0/31 (0%)6/31 (19.4%)
POS Vehicle First, Then LDP Vehicle0/45 (0%)0/45 (0%)2/45 (4.4%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPOS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP Vehicle
Instillation site erythemaGeneral disorders6/443/302/310/45
Installation site painGeneral disorders4/443/300/311/45
Eye irritationEye disorders3/440/300/310/45
Conjunctival hyperaemiaEye disorders2/442/300/310/45
Visual acuity reducedEye disorders1/441/302/311/45
Lacrimation increasedEye disorders2/440/300/310/45
DysgeusiaGastrointestinal disorders1/441/300/310/45
Eye painEye disorders1/440/301/310/45
Eye pruritusEye disorders0/440/301/310/45
Intraocular pressure increasedInvestigations0/440/301/310/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
Mean53.4 ± 5.6352.8 ± 5.1152.7 ± 5.2153.2 ± 4.5553.1 ± 5.09
Sex: Female, Male
Sex: Female, Male(Participants)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
Female38231829108
Male57131540
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
Hispanic or Latino132410
Not Hispanic or Latino42272940138
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
American Indian or Alaska Native01001
Asian00123
Native Hawaiian or Other Pacific Islander00101
Black or African American331411
White40262838132
More than one race00000
Unknown or Not Reported00000
Study eye, n (%)
Study eye, n (%)(Participants)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
OD29232335110
OS1478938
Iris color, n (%)
Iris color, n (%)(Participants)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
Light blue563620
Dark blue02237
Blue with peripupillary brown1457935
Uniform green11349
Green with brown iris ring544417
Central brown and peripheral green842115
Brown with some peripheral green325414
Brown7651331
Irides type, n (%)
Irides type, n (%)(Participants)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
Light2518192688
Dark1812121860
Baseline photopic BCDVA study eye, letters read
Baseline photopic BCDVA study eye, letters read(letters read at 4 m distance)POS 0.75% First, Then LDP 0.4%POS 0.75% First, Then LDP VehiclePOS Vehicle First, Then LDP 0.4%POS Vehicle First, Then LDP VehicleTotal
Mean57.8 ± 3.4657.9 ± 2.8458.1 ± 3.0059.2 ± 3.5858.3 ± 3.31

20 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • Clinical Site 12
    Laguna Hills, California 92653, United States
  • Clinical Site 6
    Newport Beach, California 92663, United States
  • Clinical Site 13
    Crystal River, Florida 34461, United States
  • Clinical Site 5
    Longwood, Florida 32779, United States
  • Clinical Site 11
    Maitland, Florida 32751, United States
  • Clinical Site 8
    Sarasota, Florida 34239, United States
  • Clinical Site 10
    Roswell, Georgia 30041, United States
  • Clinical Site 3
    Pittsburg, Kansas 66762, United States
  • Clinical Site 18
    St Louis, Missouri 63101, United States
  • Clinical Site 16
    Poughkeepsie, New York 12603, United States
  • Clinical Site 14
    Fargo, North Dakota 58103, United States
  • Clinical Site 2
    Athens, Ohio 45701, United States
  • Clinical Site 9
    Cincinnati, Ohio 45242, United States
  • Clinical Site 7
    Cleveland, Ohio 44115, United States
  • Clinical Site 15
    Powell, Ohio 43065, United States
  • Clinical Site 4
    Warwick, Rhode Island 02888, United States
  • Clinical Site 1
    Memphis, Tennessee 38119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2021, 3 months.

Results were first posted in Aug 2023, 2 years 2 months after primary completion.

Of 13 phase 2 interventional studies under Presbyopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 8. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Dec 19, 2020
StartActual
Feb 15, 2021
Primary completionActual
May 17, 2021
CompletionActual
Jun 30, 2021
Results first posted
Aug 2, 2023
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Ocuphire Pharma, Inc.→Opus Genetics, Inc
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Sponsor Ocuphire Pharma, Inc.→Opus Genetics, Inc
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04675151
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
Feb 15, 2021
Primary completion
May 17, 2021
Completion
Jun 30, 2021
Results posted
Aug 2, 2023
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Phentolamine · Pilocarpine

Start the discussion